Tuesday, 25 January 2011

Update in the ongoing Phase II clinical trial of APG101 to treat Glioblastoma

The biopharmaceutical company Apogenix GmbH gave an update on the status of patient recruitment in its ongoing clinical Phase II trial with APG101 for the treatment of Glioblastoma Multiforme (GBM). The independent Data Safety Monitoring Board (DSMB) has recommended the unchanged continuation of the efficacy trial with APG101 in its second meeting on the basis of 25 patients treated. Clinical data show that APG101 is safe and well tolerated by patients.

In Germany the trial is being conducted in 21 study centers and 11 additional sites in Austria and Russia. In the open-label, randomized, controlled trial, patients with first or second relapse of Glioblastoma are being treated.
Patients will either be treated with APG101 and radiotherapy or with radiotherapy alone. Primary endpoint of the trial is the 6-month-rate of progression-free survival (PFS6). Secondary endpoints include overall survival, safety and tolerability of APG101, and parameters assessing the patients' quality of life.

"The positive assessment of the study by the DSMB allows us to confidently pursue our objective to prove the effectiveness of APG101 to treat Glioblastoma, thus providing a new treatment option for patients," said Dr Harald Fricke, Chief Medical Officer of Apogenix.

The principle investigator of the trial, Prof Wolfgang Wick (Clinical Cooperation Unit Neurooncology German Cancer Research Center and Department of Neurooncology University Hospital of Heidelberg) added: "Besides investigating APG101's innovative mechanism of action we will also study its efficacy in combination with reirradiation in a multicenter controlled study for the first time. We are confident that the addition of APG101 to radiotherapy is a combination that will significantly improve the treatment of recurrent Gliobastoma."

In Germany, the trial centres are located in Heidelberg, Mannheim, Frankfurt/Oder, Frankfurt/Main, Berlin, Hamburg, Ulm, Dresden, Bochum, Leipzig, Bonn, Munich, Tübingen, Stuttgart, Mainz, Regensburg, Marburg and Aachen. In Austria, the trial is being conducted in Vienna, Graz, Linz and Innsbruck.